TY - JOUR T1 - 20(S)-Ginsenoside Rh2 Suppresses Oral Cancer Cell Growth by Inhibiting the Src-Raf-ERK Signaling Pathway JF - Anticancer Research JO - Anticancer Res SP - 227 LP - 235 DO - 10.21873/anticanres.14769 VL - 41 IS - 1 AU - HAIBO ZHANG AU - JUNKOO YI AU - EUNGYUNG KIM AU - YEONSIK CHOO AU - HUANG HAI AU - KIRIM KIM AU - EUN-KYONG KIM AU - ZAEYOUNG RYOO AU - MYOUNGOK KIM Y1 - 2021/01/01 UR - http://ar.iiarjournals.org/content/41/1/227.abstract N2 - Background: 20(S)-Ginsenoside Rh2 (G-Rh2) has demonstrated therapeutic effects in many types of cancers. We aimed to investigate the potential anticancer activity and underlying mechanisms of G-Rh2 in oral cancer cells. Materials and Methods: The antigrowth effect of G-Rh2 in oral cancer cells was stimulated by cell proliferation, soft agar colony formation, and migration and invasion assay. The cell cycle and apoptosis were detected by flow cytometry. The underlying mechanism of G-Rh2 in oral cancer cells was explored by immunoblotting. Results: G-Rh2 significantly inhibited oral cancer cell growth by inducing apoptosis and cell cycle G0/G1-phase arrest. G-Rh2 inhibited oral cancer cell migration and invasion through regulation of epithelial–mesenchymal transition (EMT)-related proteins. G-Rh2 inhibited the Src/Raf/ERK signaling pathway in YD10B and Ca9-22 cells. Conclusion: G-Rh2 exerted anticancer activity in vitro by inhibiting the Src/Raf/ERK signaling pathway in oral cancer. G-Rh2 is a potential therapeutic drug for oral cancer treatment. ER -